

ACT

Dr. P. Collignon, Mr P. Southwell
 Department of Microbiology
 Royal Canberra Hospital
 PO Box 11
 WODEN, ACT 2606
 Phone: (02) 6244 2425
 Email: peter.collignon@dpa.act.gov.au

NORTHERN TERRITORY

Dr G. Lum
 Microbiology Department
 Royal Darwin Hospital
 CASUARINA, NT
 Phone: (08) 8922 8834, Fax (08) 8922 8843
 Email: glum@ozemail.com.au

References

- Maiden MCJ, Bygraves JA, Feil E, et al. Multilocus sequence typing: a portable approach to the identification of clones within populations of pathogenic microorganisms. *Proc Natl Acad Sci USA* 1998;95:3140-3145.
- Munro R, Tapsall J. Meningococcal disease in Australia. *Commun Dis Intell* 1996;20:368-371.
- National Neisseria Network. Meningococcal Isolate Surveillance Australia 1994. *Commun Dis Intell* 1995;19:286-289.
- National Neisseria Network. Meningococcal Isolate Surveillance Australia 1995. *Commun Dis Intell* 1996;20:422-424.
- The Australian Meningococcal Surveillance Programme. Annual report of the Australian Meningococcal Surveillance Programme 1996. *Commun Dis Intell* 1997;21:217-221.
- Australian Meningococcal Surveillance Programme. Annual report of the Australian Meningococcal Surveillance Programme. *Commun Dis Intell* 1998;22:205-211.
- Australian Gonococcal Surveillance Programme. Penicillin sensitivity of gonococci in Australia: development of an Australian gonococcal surveillance programme. *Br J Vener Dis* 1984;60:226-230.
- Ashton FE, Ryan JA, Borczyk DA, Caugant DA, Mancino L, Huang D. Emergence of a virulent clone of *Neisseria meningitidis* serotype 2a that is associated with meningococcal group C disease. *Canada J Clin Microbiol* 1991;29:2489-2943.
- Maiden MCJ, Spratt BG. Meningococcal conjugate vaccines: new opportunities and new challenges. *Lancet* 1999;354:615-616.
- CDC. Serogroup Y meningococcal disease – Illinois, Connecticut, and selected areas, United States, 1989-1996. *MMWR* 1996;45:1010-1013.

Changes to the Editorial team

The production team for *CDI* has recently farewelled the Editor Eddie O'Brien, and welcomed our new Editor, Jenny Thomson. Eddie's valuable input, skills and expertise, as well as his cheerful interaction as a team member will be missed. We wish Eddie well in his new

position and thank him for his contribution to *CDI*. Jenny Thomson comes to us with qualifications and experience that will greatly benefit *CDI*. We welcome Jenny to the team and look forward to her ongoing input to the quality and development of the publication.

Australian recommendations for the influenza vaccine composition for the year 2000 season

The meeting of the Australian Influenza Vaccine Committee (AIVC) was convened on 7 October 1999 and reconvened on 9 November.

Having considered the information on international surveillance by the WHO, and recent epidemiological data and strain characterisation presented at both AIVC meetings, the Committee decided that the composition of vaccines for the year 2000 season should be as follows:

- **A (H3N2):** a A/Sydney/5/97 (H3N2) - like strain, 15 µg HA per dose
- **A (H1N1):** a A/New Caledonia/20/99 (H1N1) - like strain, 15 µg HA per dose
- **B:** a B/Beijing/184/93 - like strain, 15 µg HA per dose

It was also determined that the following viruses are suitable vaccine strains:

- A/Sydney/5/97 (IVR-108 and RESVIR-13) are A/Sydney/5/97 (H3N2)-like strains
- A/New Caledonia/20/99 (IVR-116) is an A/New Caledonia/20/99 (H1N1)-like strain
- B/Yamanashi/166/98 is a B/Beijing/184/93-like strain